Summary & Overview
CPT 0327U: Vasistera™ cfDNA Noninvasive Prenatal Test
Headline: CPT code 0327U: Proprietary Natera Vasistera™ cfDNA Noninvasive Prenatal Test
Lead: CPT code 0327U designates Vasistera™, a proprietary noninvasive prenatal test (NIPT) from Natera, Inc., that evaluates cell–free DNA (cfDNA) in maternal plasma to estimate the likelihood of fetal aneuploidies such as trisomy 21, 13, and 18. As a PLA code, 0327U is uniquely tied to a single manufacturer's commercial assay and is used when that specific test is performed.
What this code represents and why it matters: PLA codes like CPT code 0327U signal the growing role of manufacturer-specific genomic assays in prenatal screening. These tests influence clinical workflows for early pregnancy screening, laboratory operations for centralized cfDNA analysis, and payer coverage decisions given their proprietary nature.
Key payers covered: Analysis includes major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Overview of reader takeaways: Readers will learn the clinical context of CPT code 0327U as a cfDNA-based NIPT, where the service is typically performed, and the implications of PLA designation for billing and payer policy. The publication provides benchmarks for usage and coverage trends, summarizes relevant payer approaches and policy updates, and explains operational considerations for laboratories and clinicians using proprietary NIPT platforms.
Scope: Content is national in scope and focuses on coding, clinical application, payer considerations, and operational context for CPT code 0327U.
Billing Code Overview
CPT code 0327U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Vasistera™ noninvasive prenatal test from Natera, Inc. The assay uses cell–free DNA (cfDNA) from a maternal plasma specimen to analyze select fetal DNA sequences on an automated platform and applies an algorithm to calculate the likelihood of fetal aneuploidies, including trisomy 21 (Down syndrome), trisomy 13 (Edwards syndrome), and trisomy 18 (Patau syndrome).
Service Type: Noninvasive prenatal screening (NIPT) using maternal plasma cfDNA with algorithmic analysis
Typical Site of Service: Reference or specialty laboratory; specimen collection typically occurs in outpatient clinics or phlebotomy sites with testing performed in a centralized laboratory
Clinical & Coding Specifications
Clinical Context
A pregnant patient in the first or early second trimester presents for prenatal screening and requests noninvasive prenatal testing (NIPT) for common fetal aneuploidies. The ordering clinician (obstetrician-gynecologist or maternal-fetal medicine specialist) documents gestational age, obstetric history, and indication such as advanced maternal age, positive maternal serum screen, abnormal ultrasound finding, or patient preference. A blood draw is performed in an ambulatory clinic or outpatient lab; a maternal plasma specimen is collected into appropriate cfDNA collection tubes, labeled, and shipped to the performing laboratory (Natera, Inc.). The laboratory performs the proprietary assay Vasistera™ using automated cfDNA extraction, targeted analysis of selected sequences, and an algorithm to calculate the likelihood of trisomy 21, trisomy 13, and trisomy 18. Results are reported to the ordering clinician with an interpretation indicating high‑ or low‑likelihood for each condition and recommended follow up options. Typical site of service is outpatient ambulatory care, obstetric clinic, or an independent clinical laboratory remote from the ordering site. Service type: Proprietary Laboratory Analyses (PLA) — high‑complexity molecular diagnostic test billed by the performing laboratory using code 0327U.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/Not Applicable | Use when no other modifier applies; standard reporting for laboratory PLA service. |